Hollis-Eden retains Burrill LLC for advisory services
Hollis-Eden Pharmaceuticals has retained Burrill LLC to provide exclusive strategic advisory services, with an initial focus on partnering Hollis-Eden's lead program Apoptone, currently in Phase I/II development for hormone-refractory prostate cancer. :theflyonthewall.com
News For HEPH From The Last 14 Days
Check below for free stories on HEPH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
